

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10570229	
	Filing Date		2006-02-28	
	First Named Inventor		Biggadike et al.	
	Art Unit		1624	
	Examiner Name		Berch, Mark L.	
	Attorney Docket Number		PB60476USw	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	0325460	EP			1992 - 10	
	2	0434450	EP			1999 - 07	
	3	0628044	EP			1994 - 12	

/Mark Berch/ (02/25/2009)

EFS Web 2.1.5

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10570229
	Filing Date		2006-02-28
	First Named Inventor		Biggadike et al.
	Art Unit		1624
	Examiner Name		Berch, Mark L.
	Attorney Docket Number		PB60476USw

	4	0741710	EP			1996 - 11	<input type="checkbox"/>
	5	95/21161	WO			1995 - 08	<input type="checkbox"/>
	6	98/52949	WO			1998 - 11	<input type="checkbox"/>
	7	99/19327	WO			1999 - 04	<input type="checkbox"/>
	8	00/19327	WO			2000 - 04	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Berge et al., "Pharmaceutical Salts", J. of Pharm. Sci. Vol. 66(1), pp. 1-19, 1977	<input type="checkbox"/>
	2	Daluge et al., "An Efficient, Scalable synthesis of theh HIV Reverse Transcriptase Inhibitor Ziagen® (1592U89)", Nucleosides, Nucleotides & Nucleic Acids, Vol. 19, pp. 297-327, 2000	<input type="checkbox"/>
	3	Fleisher et al., "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews, Vol 19, pp. 115-130, 1996	<input type="checkbox"/>
	4	Legraverend et al., "Synthesis of a New Series of Purine Derivatives and their Anti-Cyclin-Dependent Kinase Activities", J. Heterocyclic Chem., Vol 38, pp. 299-303, 2001	<input type="checkbox"/>

/Mark Berch/ (02/25/2009)